These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18431034)

  • 21. Bone turnover marker monitoring in osteoporosis treatment response.
    Tan RZ; Loh TP; Vasikaran S
    Eur J Endocrinol; 2020 Jun; 183(1):C5-C7. PubMed ID: 32504486
    [No Abstract]   [Full Text] [Related]  

  • 22. [Determinants of bone quality and strength independent of bone remodeling].
    Saito M; Marumo K
    Clin Calcium; 2016 Jan; 26(1):29-41. PubMed ID: 26728528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
    Fukunaga M
    Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Osteoporosis in patients with diabetes mellitus].
    Yamauchi M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():526-30. PubMed ID: 18161160
    [No Abstract]   [Full Text] [Related]  

  • 25. Histomorphometric changes following treatment for osteoporosis.
    Moreira CA; Dempster DW
    J Endocrinol Invest; 2017 Sep; 40(9):895-897. PubMed ID: 28550463
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-osteoporotic drugs and vascular calcification: the bidirectional calcium traffic.
    Yavropoulou MP; Pikilidou M; Yovos JG
    J Vasc Res; 2014; 51(1):37-49. PubMed ID: 24280985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of SERMs on bone health. SERM and metabolic markers of bone].
    Takami M; Shimada H
    Clin Calcium; 2010 Mar; 20(3):365-71. PubMed ID: 20190366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone turnover markers: Defining a therapeutic target.
    Brown JP
    Clin Biochem; 2016 May; 49(7-8):527-8. PubMed ID: 27059648
    [No Abstract]   [Full Text] [Related]  

  • 29. The calcium-sensing receptor in bone metabolism: from bench to bedside and back.
    Cianferotti L; Gomes AR; Fabbri S; Tanini A; Brandi ML
    Osteoporos Int; 2015 Aug; 26(8):2055-71. PubMed ID: 26100412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the combined extracts of Herba Epimedii and Fructus Ligustri Lucidi on bone mineral content and bone turnover in osteoporotic rats.
    Liu RH; Kang X; Xu LP; Nian HL; Yang XW; Shi HT; Wang XJ
    BMC Complement Altern Med; 2015 Apr; 15():112. PubMed ID: 25889254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Assessment of bone quality. Effects of bisphosphonates, raloxifene, alfacalcidol, and menatetrenone on bone quality: collagen cross-links, mineralization, and microdamage].
    Saito M
    Clin Calcium; 2008 Mar; 18(3):364-72. PubMed ID: 18310825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of antiresorptive therapy on the structural and material properties of bone strength].
    Kishimoto H
    Clin Calcium; 2016 Jan; 26(1):107-15. PubMed ID: 26728537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination anabolic and antiresorptive therapy for osteoporosis.
    Cusano NE; Bilezikian JP
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From Bone Cell Biology to Novel Therapies of Osteoporosis.
    Hofbauer LC
    Drug Res (Stuttg); 2015 Nov; 65 Suppl 1():S14-5. PubMed ID: 26536179
    [No Abstract]   [Full Text] [Related]  

  • 35. Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?
    Liu J; Zhang H; Dong Y; Jin Y; Hu X; Cai K; Ma J; Wu G
    Med Hypotheses; 2014 Dec; 83(6):694-6. PubMed ID: 25459136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Updates on Lifestyle-Related Diseases and Bone Metabolism. Teriparatide for osteoporosis associated with lifestyle-related diseases].
    Fukumoto S
    Clin Calcium; 2014 Nov; 24(11):1701-5. PubMed ID: 25355155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of bone markers in the evaluation and follow-up of osteoporotic patients: why are the markers poorly accepted by clinicians?
    Stepan JJ
    J Endocrinol Invest; 2003 May; 26(5):458-63. PubMed ID: 12906375
    [No Abstract]   [Full Text] [Related]  

  • 38. Bone density vs bone quality: what's a clinician to do?
    Licata A
    Cleve Clin J Med; 2009 Jun; 76(6):331-6. PubMed ID: 19487553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Problems of osteoporosis: study of biochemical markers of bone metabolism].
    Nasonov EL
    Klin Med (Mosk); 1998; 76(5):20-5. PubMed ID: 9644930
    [No Abstract]   [Full Text] [Related]  

  • 40. [New bone density conservation agents for osteoporosis under research and development: Ibandronate].
    Tanaka I; Hashimoto J; Oshima H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():426-32. PubMed ID: 18161144
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.